Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
success tags : Phase 1 save search
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
Published: 2023-03-28 (Crawled : 12:00) - globenewswire.com
PSTV | $1.6914 -4.17% -0.57% 7.2K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: -2.68%
trial therapeutics plus phase 1
Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Published: 2023-02-13 (Crawled : 13:20) - prnewswire.com
MBRX | News | $4.5235 5.69% 6.75% 50K
|
Health Technology
|
| O: 5.82%
H: 4.84%
C: -4.84%
treatment topline leukemia trial phase 1
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
Published: 2022-09-06 (Crawled : 11:00) - biospace.com/
MNKD | $4.08 -0.49% -0.49% 1.3M
|
Health Technology
|
| O: 0.79%
H: 0.13%
C: -6.04%
study phase 1
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study
Published: 2022-08-30 (Crawled : 13:20) - biospace.com/
CNTB | $1.52 -1.93% -2.65% 62K
|
Professional, Scientific, and T...
|
| O: 0.35%
H: 1.39%
C: -2.08%
cbp-174 biopharma study phase 1
Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02
Published: 2022-05-10 (Crawled : 12:20) - biospace.com/
EVAX | $4.22 2.68% 2.38% 35K
|
Manufacturing
|
| O: 33.26%
H: 0.0%
C: 0.0%
evx-02 biotech trial cancer phase 1
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
Published: 2022-03-29 (Crawled : 12:20) - biospace.com/
CYBN | News | $0.3699 -1.47% -2.68% 1.6M
|
n/a
|
| O: 1.3%
H: 2.56%
C: 1.85%
cyb003 trial preclinical pre-clinical phase 1 psilocybin
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
Published: 2022-01-12 (Crawled : 14:00) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: 0.01%
H: 0.04%
C: -0.11%
phase 1 fibrosis
Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial
Published: 2022-01-11 (Crawled : 13:30) - biospace.com/
NBIO | $0.0924 -3.25% 15.32% 450
|
|
| O: 0.17%
H: 0.0%
C: 0.0%
phase 1 trial phase 2 phase 3 cancer train
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
Published: 2022-01-04 (Crawled : 20:00) - biospace.com/
MNMD | $8.91 -6.51% -6.84% 1.6M
|
n/a
|
| O: -1.32%
H: 1.33%
C: -1.33%
trial phase 1 phase 2 phase 3
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
GHRS | $11.19 1.82% 1.52% 250K
|
Manufacturing
|
| O: 0.05%
H: 29.33%
C: 21.8%
treatment phase 2 research trial phase 1 depression
BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile
Published: 2021-11-29 (Crawled : 15:00) - biospace.com/
BETRF | $0.0721 -6.36% -3.71% 15K
|
Health Technology
|
| O: -2.17%
H: 5.94%
C: -1.2%
phase 2 trials trial covid clinical trials phase 1
Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide
Published: 2021-11-22 (Crawled : 14:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -3.5%
H: 1.43%
C: -4.88%
phase 1 phase 1b trial phase 2b
Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers
Published: 2021-11-16 (Crawled : 13:30) - globenewswire.com
OTLC | $0.042 2.69% -44.63% 100K
|
Manufacturing
|
| O: 4.26%
H: 8.42%
C: 5.92%
phase 1 cancer trial
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
Published: 2021-11-15 (Crawled : 09:00) - biospace.com/
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ADXN | News | $20.96 -4.73% 8.37% 19K
|
Health Technology
|
| O: 2.85%
H: 1.14%
C: 1.14%
phase 1 phase 2 xin phase 3
SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp
Published: 2021-11-09 (Crawled : 14:00) - globenewswire.com
SCYX | $1.405 -1.06% 3.4% 80K
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: 0.0%
phase 1 trial phase 2 phase 3
Enteris BioPharma Announces Successful Completion of Phase 1 Clinical Trial of Optimized Peptelligence® Oral Leuprolide
Published: 2021-10-04 (Crawled : 15:00) - biospace.com/
SWKH | $17.34 0.06% -0.87% 3.7K
|
Miscellaneous
|
| O: -0.76%
H: 5.82%
C: 3.62%
biopharma phase 1 trial phase 3 phase 2
Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial
Published: 2021-09-08 (Crawled : 12:00) - biospace.com/
LBPH | $18.01 5.94% 5.61% 500K
|
Manufacturing
|
| O: -0.58%
H: 1.75%
C: 1.55%
phase 1 trial phase 1b phase 2b
Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Published: 2021-08-25 (Crawled : 14:15) - globenewswire.com
RFL 4 | $1.71 -3.93% 4.68% 11K
|
Finance
|
| O: 1.15%
H: 17.78%
C: 17.14%
phase 2 phase 1 cancer trial phase 1b cpi-613 gemcitabine phase 2b
Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner
Published: 2021-03-16 (Crawled : 14:00) - biospace.com/
PLRX | $12.19 -5.21% -5.15% 360K
|
Health Technology
|
| O: 1.12%
H: 2.4%
C: -0.41%
phase 1 phase 3 phase 2
Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients
Published: 2021-02-24 (Crawled : 14:01) - globenewswire.com
LGVN | News P 0 d | $2.01 -3.83% -4.24% 970K
|
|
| O: 0.47%
H: 20.74%
C: 18.42%
heart phase 1 injection phase 3 phase 2 syndros lomecel-b
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
UMAC | $1.55 0.65% 16.13% 3K
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
VLD 4 | $0.2638 -3.65% 13.27% 2.6M
|
Manufacturing
TAOP | $1.08 13.01% 11.51% 19K
|
Technology Services
MGLD 4 | $1.13 5.61% 10.62% 200
|
Manufacturing
NURO | $3.65 2.24% 10.3% 3.9K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.